Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody

Virology

Volumn 392, Issue 1, 2009, Pages 103-113

  Wahala, W M P B ^a   Kraus, Annette A ^a   Haymore, Laura B ^a   Accavitti Loper, Mary Ann ^b   de Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Antibody; Dengue; Flavivirus; Human immune serum; Recombinant viral protein; Virus neutralization

Indexed keywords

ANTISERUM; CROSS REACTING ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE DOMAIN PROTEIN III; VIRUS ENVELOPE PROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; DENGUE VIRUS; HUMAN; IMMUNITY; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN FUNCTION; SECONDARY INFECTION; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DENGUE VIRUS; HUMANS; MICE; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS;

DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRUS;

EID: 69249213373     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.06.037     Document Type: Article

References (38)

1. Babu J.P., Pattnaik P., Gupta N., Shrivastava A., Khan M., and Rao P.V. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26 36 (2008) 4655-4663
2. Beasley D.W., Holbrook M.R., Travassos Da Rosa A.P., Coffey L., Carrara A.S., Phillippi-Falkenstein K., Bohm Jr. R.P., Ratterree M.S., Lillibridge K.M., Ludwig G.V., Estrada-Franco J., Weaver S.C., Tesh R.B., Shope R.E., and Barrett A.D. Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J. Clin. Microbiol. 42 6 (2004) 2759-2765
3. Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., Lopez C., Martinez R., Castro J., Santana E., Hermida L., Guillen G., and Guzman M.G. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 10 (2008) 1016
4. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75 16 (2001) 7769-7773 10.1128/JVI.75.16.7769-7773.2001
5. Crill W.D., Hughes H.R., Delorey M.J., and Chang G.J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4 4 (2009) e4991
6. Edelman R. Dengue vaccines approach the finish line. Clin. Infect. Dis. 45 Suppl. 1 (2007) S56-60
7. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., and Khanna N. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg. 79 3 (2008) 353-363
8. Goncalvez A.P., Men R., Wernly C., Purcell R.H., and Lai C.J. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J. Virol. 78 23 (2004) 12910-12918
9. Gromowski G.D., and Barrett A.D. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366 (2007) 349-360
10. Gromowski G.D., Barrett N.D., and Barrett A.D. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82 17 (2008) 8828-8837
11. Halstead S.B. Dengue. Curr. Opin. Infect Dis. 15 5 (2002) 471-476
12. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003) 421-467
13. Hapugoda M.D., Batra G., Abeyewickreme W., Swaminathan S., and Khanna N. Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. Clin. Vaccine Immunol. 14 11 (2007) 1505-1514
14. Henchal E.A., McCown J.M., Burke D.S., Seguin M.C., and Brandt W.E. Epitopic Analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34 1 (1985) 162-169
15. Holbrook M.R., Shope R.E., and Barrett A.D. Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses. J. Clin. Microbiol. 42 9 (2004) 4101-4110
16. Kraus A.A., Messer W., Haymore L.B., and de Silva A.M. Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45 (2007) 3777-3780
17. Lai C.Y., Tsai W.Y., Lin S.R., Kao C.L., Hu H.P., King C.C., Wu H.C., Chang G.J., and Wang W.K. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82 13 (2008) 6631-6643
18. Lin B., Parrish C.R., Murray J.M., and Wright P.J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202 2 (1994) 885-890
19. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., Diamond M.S., Kuhn R.J., and Rossmann M.G. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct., Mol. Biol. 15 3 (2008) 312-317
20. Ludolfs D., Schilling S., Altenschmidt J., and Schmitz H. Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens. J. Clin. Microbiol. 40 11 (2002) 4317-4320
21. Maillard R.A., Jordan M., Beasley D.W., Barrett A.D., and Lee J.C. Long range communication in the envelope protein domain III and its effect on the resistance of West Nile virus to antibody-mediated neutralization. J. Biol. Chem. 283 1 (2008) 613-622
22. Modis Y., Ogata S., Clements D., and Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100 12 (2003) 6986-6991
23. Modis Y., Ogata S., Clements D., and Harrison S.C. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79 2 (2005) 1223-1231
24. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., and Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437 7059 (2005) 764-769
25. Nybakken G.E., Nelson C.A., Chen B.R., Diamond M.S., and Fremont D.H. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80 (2006) 11467-11474
26. Oliphant T., Nybakken G.E., Austin S.K., Xu Q., Bramson J., Loeb M., Throsby M., Fremont D.H., Pierson T.C., and Diamond M.S. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81 21 (2007) 11828-11839 10.1128/JVI.00643-07
27. Rey F.A., Heinz F.X., Mandl C., Kunz C., and Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375 6529 (1995) 291-298
28. Roehrig J.T. Antigenic structure of flavivirus proteins. Adv. Virus Res. 59 (2003) 141-175
29. Roehrig J.T., Bolin R.A., and Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246 2 (1998) 317-328
30. Rothman A.L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113 7 (2004) 946-951
31. Sanchez M.D., Pierson T.C., Degrace M.M., Mattei L.M., Hanna S.L., Del Piero F., and Doms R.W. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359 2 (2007) 336-348
32. Schlesinger J.J., Brandriss M.W., and Walsh E.E. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 68 Pt 3 (1987) 853-857
33. Serafin I.L., and Aaskov J.G. Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch. Virol. 146 12 (2001) 2469-2479
34. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., and Diamond M.S. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81 23 (2007) 12816-12826 10.1128/JVI.00432-07
35. Vázquez S., Guzmán M.G., Guillen G., Chinea G., Pérez A.B., Pupo M., Rodriguez R., Reyes O., Garay H.E., Delgado I., García G., and Alvarez M. Immune response to synthetic peptides of dengue prM protein. Vaccine 20 13-14 (2002) 1823-1830
36. Volk D.E., Beasley D.W., Kallick D.A., Holbrook M.R., Barrett A.D., and Gorenstein D.G. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J. Biol. Chem. 279 37 (2004) 38755-38761
37. Volk D.E., Lee Y.C., Li X., Thiviyanathan V., Gromowski G.D., Li L., Lamb A.R., Beasley D.W., Barrett A.D., and Gorenstein D.G. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364 1 (2007) 147-154
38. Yu S., Wuu A., Basu R., Holbrook M.R., Barrett A.D., and Lee J.C. Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses. Biochemistry 43 28 (2004) 9168-9176